Halofuginone inhibits angiogenesis and growth in implanted metastatic rat brain tumor model - An MRI study

Neoplasia

Volumn 6, Issue 5, 2004, Pages 480-489

  Abramovitch, Rinat ^a   Itzik, Anna ^a   Harel, Hila ^a   Nagler, Arnon ^a,b   Vlodavsky, Israel ^c   Siegal, Tali ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Angiogenesis; Brain tumor; Halofuginone; MRI; Vessel cooption

Indexed keywords

ANGIOGENESIS INHIBITOR; HALOFUGINONE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN METASTASIS; BRAIN TUMOR; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; MALIGNANT FIBROUS HISTIOCYTOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; TUMOR GROWTH; TUMOR VASCULARIZATION;

EID: 6944224022     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1593/neo.03520     Document Type: Article

References (47)

1. Bernsen HJJA and Van der Kogel AJ (1999). Antiangiogenic therapy in brain tumor models. J Neuro-Oncol 45, 247-255.
2. Reijneveld JC, Voest EE, and Taphoorn MJB (2000). Angiogenesis in malignant primary and metastatic brain tumors. J Neurol 247, 597-608.
3. Folkman J (1985). Tumor angiogenesis. Adv Cancer Res 43, 175-203.
4. Vidal S, Kovacs K, Lloyd RV, Meyer FB, and Scheithauer BW (2002). Angiogenesis in patients with craniopharyngiomas correlation with treatment and outcome. Cancer 94, 738-745.
5. Vidal S, Kovacs K, Horvath E, Scheithauer BW, Turoki T, and Lloyd RV (2001). Microvessel density in pituitary adenomas and carcinomas. Virchows Arch 438, 595-602.
6. Korkolopoulou P, Patsouris E, Kavantzas N, Konstantinidou AE, Christodoulou P, Thomas-Tsagli E, Pananikolaou A, Eftychiadis C, Pavlopoulos PM, Angelidakis D, Rologis D, and Davaris P (2002). Prognostic implications of microvessel morphometry in diffuse astrocytic neoplasms. Neuropathol Appl Neurobiol 28, 57-66.
7. Iruela-Arispe ML, Hasselaar P, and Sage H (1991). Differential expression of extracellular matrix proteins is correlated with angiogenesis in vitro. Lab Invest 64, 174-186.
8. Iruela-Arispe ML, Diglio CA, and Sage H (1991). Modulation of extra-cellular matrix proteins by endothelial cells undergoing angiogenesis in vitro. Arterioscler Thromb 11, 805-815.
9. Madri JA and Sten KS (1982). Aortic endothelial cell migration I matrix requirements and composition. Am J Pathol 106, 180-186.
10. Montesano R, Orci L, and Vassalli P (1983). In vitro rapid organization of endothelial cells into capillary-like networks is promoted by collagen matrices. J Cell Biol 97, 1648-1652.
11. Jackson CJ and Jenkins KL (1991). Type I collagen fibrils promote rapid vascular tube formation upon contact with the apical side of cultured endothelium. Exp Cell Res 192, 319-323.
12. Senger DR, Claffey KP, Benes JE, Perruzzi CA, and Sergiou A (1997). Angiogenesis promoted by vascular endothelial growth factor: regulation through a1b1 and a2b1 integrins. Proc Natl Acad Sci USA 94, 13612-13617.
13. Pines M, Vlodavsky I, and Nagler A (2000). Halofuginone: from veterinary use to human therapy. Drug Dev Res 50, 371-378.
14. Pines M and Nagler A (1997). Halofuginone - a novel anti-fibrotic therapy. Gen Pharmacol 30, 445-450.
15. Elkin M, Miao HQ, Nagler A, Aingorn E, Reich R, Hemo I, Dou HL, Pines M, and Vlodavsky I (2000). Halofuginone: a potent inhibitor of critical steps in angiogenesis progression. FASEB J 14, 2477-2485.
16. Abramovitch R, Dafni H, Neeman M, and Nagler A (1999). Inhibition of neovascularization and tumor growth, and facilitation of wound repair, by halofuginone, an inhibitor of collagen type I synthesis. Neoplasia 1, 321-329.
17. Gavish Z, Pinthus JH, Barak V, Ramon J, Nagler A, Eshhar Z, and Pines M (2002). Growth inhibition of prostate cancer xenografts by halofuginone. Prostate 51, 73-83.
18. Boehm T, Folkman J, Browder T, and O'Reilly MS (1997). Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390, 404-407.
19. Millauer B, Shwver LK, Plate KH, Risau W, and Ullrich A (1994). Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367, 576-579.
20. O'Reilly MS, Holmgren L, Chen C, and Folkman J (1996). Angiogstatin induces and sustains dormancy of human primary tumors in mice. Nat Med 2, 689-692.
21. Holash J, Maisonpierre PC, Compon D, Boland P, Alexander CR, Zagzag D, and Yancopoulos GD (1999). Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284, 1994-1998.
22. Kusters B, Leenders WPJ, Wesseling P, Smits D, Verrijp K, Ruiter DJ, Peters JPW, Van der Kogel AJ, and de Waal RMW (2002). Vascular endothelial growth factor-A165 induces progression of melanoma brain metastases without induction of sprouting angiogenesis. Cancer Res 62, 341-345.
23. Siegal T, Horowitz A, and Gabizone A (1995). Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. J Neurosurg 83, 1029-1037.
24. Shoshan Y and Siegal T (1996). Control of vasogenic edema in a brain tumor model: comparison between dexamethasone and superoxide dismutase. Neurosurgery 39, 1206-1213.
25. Zhou R, Mazurchuk R, and Straubinger RM (2002). Antivasculature effects of doxorubicin-containing liposomes in an intracranial rat brain tumor model. Cancer Res 62, 2561-2566.
26. Ross BD, Chenevert TL, Garwood M, Kim B, Stegman LD, Ben-Yoseph O, Zwolshen J, Rehemtulla A, and Sunkara PS (2003). Evaluation of (E)-2′-deoxy-2′-(fluoromethylene)cytidine on the 9L rat brain tumor model using MRI. NMR Biomed 16, 67-76.
27. Kish PE, Blaivas M, Strawderman M, Muraszko KM, Ross DA, Ross BD, and McMahon G (2001). Magnetic resonance imaging of ethyl-nitrosourea-induced rat gliomas: a model for experimental therapeutics of low-grade gliomas. J Neuro-Oncol 53, 243-257.
28. Gossmann A, Helbich TH, Kuriyama N, Ostrowitzki S, Roberts TP, Shames DM, van Bruggen N, Wendland MF, Israel MA, and Brasch RC (2002). Dynamic contrast-enhanced magnetic resonance imaging as a surrogate marker of tumor response to anti-angiogenic therapy in a xenograft model of glioblastoma multiforme. J Magn Reson Imaging 15, 233-240.
29. Leenders W, Kusters B, Pikkemaat J, Wesseling P, Ruiter D, Heerschap A, Barentsz J, and de Waal RM (2003). Vascular endothelial growth factor-A determines detectability of experimental melanoma brain metastasis in GD-DTPA-enhanced MRI. Int J Cancer 105, 437-443.
30. Cha S, Johnson G, Wadghiri YZ, Jin O, Babb J, Zagzag D, and Turnbull DH (2003). Dynamic, contrast-enhanced perfusion MRI in mouse gliomas: correlation with histopathology. Magn Reson Med 49, 848-855.
31. Robinson SP, McIntyre DJ, Checkley D, Tessier JJ, Howe FA, Griffiths JR, Ashton SE, Ryan AJ, Blakey DC, and Waterton JC (2003). Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging. Br J Cancer 88, 1592-1597.
32. Chenevert TL, Meyer CR, Moffat BA, Rehemtulla A, Mukherji SK, Gebarski SS, Quint DJ, Robertson PL, Lawrence TS, Junck L, Taylor JM, Johnson TD, Dong Q, Muraszko KM, Brunberg JA, and Ross BD (2002). Diffusion MRI: a new strategy for assessment of cancer therapeutic efficacy. Mol Imaging 1, 336-343.
33. Tailor DR, Roy A, Regatte RR, Charagundla SR, McLaughlin AC, Leigh JS, and Reddy R (2003). Indirect 17(O)-magnetic resonance imaging of cerebral blood flow in the rat. Magn Reson Med 49, 479-487.
34. Robinson SP, Rijken PF, Howe FA, McSheehy PM, van der Sanden BP, Heerschap A, Stubbs M, Van der Kogel AJ, and Griffiths JR (2003). Tumor vascular architecture and function evaluated by non-invasive susceptibility MRI methods and immunohistochemistry. J Magn Reson Imaging 17, 445-454.
35. Abramovitch R, Dafni H, Smouha E, Benjamin LE, and Neeman M (1999). In vivo prediction of vascular susceptibility to vascular endothelial growth factor withdrawal: magnetic resonance imaging of C6 rat glioma in nude mice. Cancer Res 59, 5012-5016.
36. Ogawa S, Lee TM, Kay AR, and Tank DW (1990). Brain magnetic resonance imaging with contrast dependent on blood oxygenation. Proc Natl Acad Sci USA 87, 9868-9872.
37. van Zijl PC, Eleff SM, Ulatowski JA, Oja JM, Ulug AM, Traystman RJ, and Kauppinen RA (1998). Quantitative assessment of blood flow, blood volume and blood oxygenation effects in functional magnetic resonance imaging. Nat Med 4, 159-167.
38. Goldshmidt O, Zcharia E, Abramovitch R, Metzger S, Guatta-Rangini Z, Aingorn H, Friedmann Y, Mitrani E, and Vlodavsky I (2002). Cell surface expression and secretion of heparanase markedly promote tumor angiogenesis and metastasis. Proc Natl Acad Sci USA 99, 10031-10036.
39. Ross BD, Zhao YJ, Neal ER, Stegman LD, Ercolani M, Ben-Yoseph O, and Chenevert TL (1998). Contributions of cell kill and posttreatment tumor growth rates to the repopulation of intracerebral 9L tumors after chemotherapy: an MRI study. Proc Natl Acad Sci USA 95, 7012-7017.
40. Abramovitch R, Frenkiel D, and Neeman M (1998). Analysis of subcutaneous angiogenesis by gradient echo magnetic resonance imaging. Magn Reson Med 39, 813-824.
41. Siegal T, Rubinstein R, Tzuk-Shina T, and Gomori JM (1997). Utility of relative cerebral blood volume mapping derived from perfusion magnetic resonance imaging in the routine follow up of brain tumors. J Neurosurg 86, 22-27.
42. Benjamin LE, Golijanin D, Itin A, Pode D, and Keshet E (1999). Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103, 159-165.
43. Gross DJ, Reibstein I, Weiss L, Slavin S, Stein I, Neeman M, Abramovitch R, and Benjamin LE (1999). The antiangiogenic agent linomide inhibits the growth rate of von Hippel-Lindau paraganglioma xenografts to mice. Clin Cancer Res 5, 3669-3675.
44. Blouw B, Song H, Tihan T, Bosze J, Ferrara N, Gerber HP, Johnson RS, and Bergers G (2003). The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 4, 133-146.
45. Bergers G and Benjamin LE (2003). Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3, 401-410.
46. Rubenstein JL, Kim J, Ozawa T, Zhang M, Westphal M, Deen DF, and Shuman MA (2000). Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2, 306-314.
47. Kunkel P, Ulbricht U, Bohlen P, Brockmann MA, Filibrandt R, Stavrou D, Westphal M, and Lamszus K (2001). Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 61, 6624-6628.